Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vertex Selects VX-445 For CF Triple Therapy Due To Safety/Tolerability

Executive Summary

Already dominant in cystic fibrosis, Vertex hopes its triple regimen will address roughly 90% of the patient population. It also hopes the benefits of the triple will smooth EU reimbursement talks.

You may also be interested in...



Vertex Buys Semma, Gaining Cell Therapy-Based Type 1 Diabetes Treatments

Semma's innovative technology involves growing insulin-producing beta cells from stem cells and transplanting them into the liver, but it hasn't been tested in humans yet.

Keeping Track: US FDA Clears Two More Biosimilars, First Non-Injectable Glucagon

The latest drug development news and highlights from our US FDA Performance Tracker.

Vertex' Dueling Phase III Programs Pay Off In NDA Submission Speed

Next-generation CFTR corrector elexacaftor aims to be first cystic fibrosis product with minimal function mutations claim after winning out over VX-659 thanks to tolerability advantage in dueling Phase III programs testing combination with the components of Vertex’ Symdeko.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM006665

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel